



## SVB Securities Served as PIPE Placement Agent to Frazier Lifesciences Acquisition Corp. (Nasdaq: FLAC) and Financial Advisor and Capital Markets Advisor to NewAmsterdam Pharma in Connection with its Completed Merger and \$235 Million PIPE

### Key Transaction Highlights

- On November 28th, NewAmsterdam Pharma Company N.V. ("NewAmsterdam") and Frazier Lifesciences Acquisition Corp. ("FLAC") announced the closing of their business combination.
- The resulting combined company commenced trading its ordinary shares and warrants on the Nasdaq Stock Market on the Nasdaq Capital Market under the symbols "NAMP" and "NAMPW" respectively.
- As a result of the business combination, NewAmsterdam received total net proceeds of approximately \$228 million, consisting approximately \$10 million from the former FLAC trust account (reflecting a final redemption rate of approximately 10 percent) and the concurrent \$228 million PIPE financing led by Frazier Lifesciences Partners and Best Capital LLC Investors, which the Company expects will support: (i)ii) further drug R&D, (ii)ii) important ongoing Phase 3 research for cardiovascular disease, including the PREVALE, COOT study.

### About NewAmsterdam Pharma

NewAmsterdam is a clinical-stage biopharmaceutical company whose mission is to improve patient care in conjunction with patients' doctors whose currently approved therapies have not been sufficiently successful or well-tolerated. NewAmsterdam is investigating breakthrough oral oral low-dose anti-CD11c therapy as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease ("CVD") patients. Results from NewAmsterdam's ROSE Phase 2b trial presented at World Scientific Sessions in 2021 included observations that patients receiving treatment 10 mg experienced a median reduction in LDL-C of 117% versus baseline in patients on high-intensity statin therapy (i.e. a 7% reduction in the placebo arm). NewAmsterdam is headquartered in the Netherlands.

### About Frazier Lifesciences Acquisition Corporation

FLAC is a blank check company incorporated as a Cayman Islands exempted company in October 2020 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. FLAC was formed to leverage the extensive experience and track record of its management team with the goal of financing a company that can both develop transformative therapies for patients in need and deliver significant returns to its investors.

For more information on this website, visit [www.svb.com](https://www.svb.com). For media inquiries, visit [www.svb.com/press](https://www.svb.com/press).

THE SELLER IS NOT AN INVESTMENT ADVISOR AND DOES NOT MAKE ANY RECOMMENDATION OR OFFER TO BUY OR SELL SECURITIES. THE SELLER HAS NOT CONDUCTED ANY INVESTMENT RESEARCH AND HAS NOT MADE ANY RECOMMENDATION OR OFFER TO BUY OR SELL SECURITIES. THE SELLER IS NOT AN INVESTMENT ADVISOR AND DOES NOT MAKE ANY RECOMMENDATION OR OFFER TO BUY OR SELL SECURITIES.

SVB SECURITIES 111 Pine Street San Francisco, CA 94111 Phone: 415.855.1000	SVB SECURITIES 200 Pine Street, Suite 200 San Francisco, CA 94111 Phone: 415.855.1000	SVB SECURITIES 200 Montgomery Street San Francisco, CA 94111 Phone: 415.855.1000	SVB SECURITIES 100 Avenue of the Americas New York, NY 10013 Phone: 212.692.1000	SVB SECURITIES 200 California Street San Francisco, CA 94111 Phone: 415.855.1000
---	--	---	---	---